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Abstract
The Sp4 transcription factor plays a critical role for both development and function of mouse hippocampus. Reduced
expression of the mouse Sp4 gene results in a variety of behavioral abnormalities relevant to human psychiatric disorders.
The human SP4 gene is therefore examined for its association with both bipolar disorder and schizophrenia in European
Caucasian and Chinese populations respectively. Out of ten SNPs selected from human SP4 genomic locus, four displayed
significant association with bipolar disorder in European Caucasian families (rs12668354, p=0.022; rs12673091, p=0.0005;
rs3735440, p=0.019; rs11974306, p=0.018). To replicate the genetic association, the same set of SNPs was examined in a
Chinese bipolar case control sample. Four SNPs displayed significant association (rs40245, p=0.009; rs12673091, p=0.002;
rs1018954, p=0.001; rs3735440, p=0.029), and two of them (rs12673091, rs3735440) were shared with positive SNPs from
European Caucasian families. Considering the genetic overlap between bipolar disorder and schizophrenia, we extended
our studies in Chinese trios families for schizophrenia. The SNP7 (rs12673091, p=0.012) also displayed a significant
association. The SNP7 (rs12673091) was therefore significantly associated in all three samples, and shared the same
susceptibility allele (A) across all three samples. On the other hand, we found a gene dosage effect for mouse Sp4 gene in
the modulation of sensorimotor gating, a putative endophenotype for both schizophrenia and bipolar disorder. The
deficient sensorimotor gating in Sp4 hypomorphic mice was partially reversed by the administration of dopamine D2
antagonist or mood stabilizers. Both human genetic and mouse pharmacogenetic studies support Sp4 gene as a
susceptibility gene for bipolar disorder or schizophrenia. The studies on the role of Sp4 gene in hippocampal development
may provide novel insights for the contribution of hippocampal abnormalities in these psychiatric disorders.
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Introduction
The Sp4 gene, a member of Sp1 family of transcription factors,
recognizes GC-rich elements in the promoter of a variety of genes.
These GC-rich sequences are readily identified in the ‘‘CpG
islands’’ around the promoters of a variety of genes [1]. Both Sp1
and Sp4 recognize the same DNA binding sequence, and
functionally substitute with each other in vitro [2]. In contrast to
the ubiquitous expression pattern of the Sp1 gene, the Sp4 gene is
restrictively expressed in nervous system [3,4]. Our previous
studies demonstrated that the complete absence of the Sp4 gene
impaired postnatal development of hippocampal dentate gyrus by
reducing cell proliferation, dendritic growth, and dendritic
arborization in Sp4 null mutant mice [5]. Moreover, hypomorphic
Sp4 mutant mice with reduced expression of the Sp4 gene
displayed vacuolization in the hippocampus as well as deficits in
sensorimotor gating and memory, putative endophenotypes for
several psychiatric disorders including schizophrenia and bipolar
disorder [4,6,7].
On the other hand, the human SP4 gene has been mapped to
chromosome 7p15, where a susceptibility locus was suggested for a
broad spectrum of human psychiatric disorders, including
schizophrenia [8,9,10], panic disorder [11,12], ADHD [13],
autism [14,15,16,17], and bipolar disorder [18,19,20]. Of these
genome linkage studies, we were particularly interested in the
finding that one locus on chromosome 7, at the marker D7S1802,
was found to associate with bipolar disorder, which is about
700 kb away from the SP4 gene [18,21]. Another genome scan
also suggested a susceptibility locus for bipolar disorder on
chromosome 7p15 [19]. All these psychiatric disorders displayed
sensorimotor gating deficit (18). We therefore hypothesized that a
susceptibility gene may contribute to the pathogenesis of these
different clinical disorders by modulating sensorimotor gating, an
endophenotype for several psychiatric disorders. Considering
deficient sensorimotor gating in Sp4 hypomorphic mice and
human SP4 gene localized in a susceptibility locus for bipolar
disorder, we therefore examined whether human SP4 gene may
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single nucleotide polymorphisms (SNPs) encompassing the human
SP4 genomic locus, and examined their association with both
bipolar disorder and schizophrenia in European and Chinese Han
populations, respectively. Significant associations were observed
between SP4 gene and bipolar disorder/schizophrenia in all three
independent samples. Interestingly, our further studies found that
the expression of mouse Sp4 gene exhibits haploinsufficiency for
modulating sensorimotor gating. Moreover, administration of
either dopamine D2 antagonists or mood stabilizers can partially
reverse the sensorimotor gating deficits.
Materials and Methods
UCSD and NIMH families with bipolar disorder
The total sample for analysis included 1872 individuals from
427 Caucasian families, approximately half of which consisted of
both parents and one affected offspring with the remaining
consisting of both parents and two or more affected offspring. The
average family consisted of 4.4 individuals in 2 generations. The
families chosen for this study derived from several sources. The
National Institute of Mental Health Genetics Initiative for Bipolar
Disorder waves 1–4 pedigree collections were collected as part of a
consortium and ascertained through a bipolar I proband, and
assessed using the Diagnostic Interview for Genetic Studies (DIGS)
[22]. Families were also drawn from the University California San
Diego consortium including collection sites at UCSD, University
of British Columbia, and University of Cincinnati [23]. These
families were ascertained through a bipolar I or bipolar II proband
and selected for the presence of at least two other mood disordered
family members. The Structured Clinical Interview for DSM-III-
R (SCID) was used to directly interview subjects for this sample.
For each collection, information from the interview, other family
informants, and medical records were then reviewed by a panel of
clinicians in order to make a final best-estimate diagnosis. DNA of
all study subjects was prepared from cultured lymphoblastoid cells.
Chinese bipolar cases and control sample
506 unrelated bipolar patients (male: 284, female: 222; average
of age: 37.8611.4 years; average age of onset: 26.7610.6 years) and
507 unrelated controls (male: 287, female: 220; age: 36.468.7 years)
were recruited for the study.All the subjectswereof Han originfrom
Anhui province. Among the 506 bipolar patients diagnosed using
DSM-IV, 419 (82.8%) patients were type I Bipolar. Final diagnosis
was made with two independent psychiatrists on the basis of
interview and medical records. All participating subjects provided
written informed consent according to procedures approved by the
Ethic Committee of Bio-X Center, Shanghai Jiao Tong University.
Chinese trio families with schizophrenia
A total of 325 trio families were collected from several different
sites with 126 families from Shanghai, 71 families from Shanxi
province, 86 families from Jilin province, and 42 families from
Changchun. All subjects were Han Chinese in origin. There were
145 female and 163 male probands with an average age of
24.066.6. Clinical diagnoses were made according to DSM-IV,
and ascertained by an independent clinician. All the subjects
provided written informed consent according to procedures
approved by the Ethic Committee of Bio-X Center, Shanghai
Jiao Tong University.
Genotyping
Human SP4 gene encompasses about 90 kb on chromosome
7p15. To conduct a comprehensive association study on Sp4 gene
with bipolar disorder in European Caucasian families, we selected
ten SNPs which started from the site 5 kb upstream of human SP4
transcription start site and ended at the site 3 kb downstream of its
transcription termination. The ten SNPs have good heterozygosity
and are representative for LD structures of human SP4 gene in
European Caucasian population according to HapMap data. The
same set of SNPs was used for replication studies in Chinese
bipolar case control sample. A subset of 5 of these SNPs with
MAFs .0.10 were genotyped in the Chinese schizophrenia trio
families. The primer pairs for the genotyping of individual SNPs
were ordered from Applied Biosystems. All SNPs were genotyped
in Caucasian and Chinese samples using the TaqMan allele
specific assay method (Applied Biosystems) according to the
manufacturer’s protocols. Concentrations and cycling parameters
were optimized to produce clusters of values for heterozygotes and
homozygotes separated by .4 standard deviations. The allele
frequency of SNP7 (rs12673091) was also confirmed by directly
sequencing in Chinese case control sample for bipolar disorder.
Genetic association analysis
In the Caucasian sample, Haploview v.4.0 [24] was used for an
assessment of linkage disequilibrium (LD) within the gene, as well
as calculations of allele frequencies and Hardy-Weinberg Equilib-
rium (HWE), based on unrelated individuals in all samples. The
program HAP [25] was used for an evaluation of the block
structure of SP4 in the Caucasian bipolar family sample, and the
resulting structure was used to inform subsequent haplotype
analyses. Haplotypes for unrelated individuals (i.e., parents) in the
sample were determined using the imperfect phylogeny phasing
method implemented in HAP. Following phasing, HAP parti-
tioned the region into haplotype blocks of correlated SNPs using
an algorithm that minimizes the number of tag SNPs [25].
Following block and haplotype identification, the phylogenetic
relationships between haplotypes were computed by optimizing a
probabilistic model that assumes exponential population growth
after a population bottleneck. Under this assumption, any variants
after the bottleneck occur in haplotypes that are also present in the
modern population. Haplotypes that have no intermediates
between them (i.e., that vary by $2 SNPs) are assumed to be
before the bottleneck and are therefore ‘‘ancestral’’ haplotypes.
‘‘Common’’ haplotypes are defined as being a single mutation or
recombination event away from the ancestral haplotypes as such
events are likely to have happened after a major population
bottleneck. The algorithm identifies ‘‘recent’’ haplotypes by
considering rare (,5%) haplotypes and explaining them with
either a single gene conversion, mutation, or recombination event
from the ‘‘common’’ haplotypes. Haploview [24] was then used to
perform the parenTDT test using single SNPs and haplotypes. In
addition to providing protection against population stratification,
the parenTDT can also add considerable power to family-based
association analyses if the parents are measured on the phenotype,
as most of ours are, and are discordant [26]. For the haplotype
analyses, counts were obtained by summing the fractional
likelihoods of each individual for each haplotype. Permutations
tests were performed to correct for multiple comparisons.
UNPHASED [27] was used for genotypic association analyses.
All association analyses were performed under a definition of
bipolar disorder that included bipolar I and II, as well as
schizoaffective disorder, bipolar-type.
Haploview v.4.0 [24] was used to calculate allele frequencies,
Hardy-Weinberg Equilibrium (HWE), and p value of both single
SNPs and haplotypes in Chinese BP case control samples. The LD
block structure was calculated using the four gamete rule, a variant
on the algorithm described by Wang et al [28]. For each marker
SP4 Gene in Bipolar Disorder
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haplotypes were computed. If all 4 are observed with at least
frequency 0.01, a recombination is deemed to have taken place.
Blocks are formed by consecutive markers where only 3 gametes
are observed. The 1% cutoff can be edited to make the definition
more or less stringent.
The family-based association analyses of the single SNPs and
haplotypes in the Chinese schizophrenia trio families were
performed using the TDTPHASE module implemented in the
UNPHASED program [29]. An E-M algorithm was used to
estimate missing genotypes and excessively rare haplotypes were
removed from the analyses.
Sp4 hypomorphic mice
The Sp4 hypomorphic mice were generated as described [4],
and maintained in both S129 and Black Swiss, respectively. The
Sp4 test cohort was generated by breeding the heterozygous Sp4
mice between the two genetic backgrounds. Therefore, all the test
mice will have the same genetic mixed S129/Black Swiss
background as the F1 generation. PCR was used for Sp4 mouse
genotyping as previously described [4]. Mice were housed in a
climate-controlled animal colony with a reversed day/night cycle.
Food (Harlan Teklab, Madison, WI) and water were available ad
libitum, except during behavioral testing. All behavioral testing
procedures were approved by the UCSD institutional animal care
and use committee prior to the onset of the experiments. Mice
were maintained in American Association for Accreditation of
Laboratory Animal Care approved animal facilities at the local
VA Hospital. This facility meets all Federal and State require-
ments for animal care.
Prepulse inhibition session
Startle reactivity was measured using eight startle chambers
(SR-LAB, San Diego Instruments, San Diego, CA) with
background noise of 65 dB and the various acoustic stimuli. All
PPI test sessions consisted of startle trials (PULSE-ALONE),
prepulse trials (PREPULSE+PULSE), and no-stimulus trials
(NOSTIM). The PULSE-ALONE trial consisted of a 40-ms
120-dB pulse of broad-band noise. PREPULSE+PULSE trials
consisted of a 20-ms noise prepulse, 80 ms delay, then a 40-ms
120-dB startle pulse (100 ms onset to onset). The acoustic prepulse
intensities were 69, 73, and 81 dB (ie 4, 8, and 16 dB above the
65-dB background noise). The NOSTIM trial consisted of
background noise only. The test session began and ended with
five presentations of the PULSE-ALONE trial; in between, each
acoustic or NOSTIM trial type was presented 10 times in a
pseudo-random order. There was an average of 15 s (range: 12–
30 s) between trials. A background noise level of 65 dB was
presented for a 10-min acclimation period and continued
throughout the test session.
Drugs
Raclopride (3 mg/kg, Sigma, St. Louis, MO, USA) was
dissolved in distilled water and injected intraperitoneally at a
volume of 5 ml/kg 10 min before the start of the test session.
Lithium chloride anhydrous (85 mg/kg, Sigma-Aldrich) was
dissolved in saline and administered i.p. at a volume of 5 ml/kg
60 min before the start of the test session. The sodium salt of
valproate (100 mg/kg, Sigma-Aldrich) was dissolved in saline and
administered i.p. at a volume of 5 ml/kg 10 min before the start of
the test session. Carbamazepine (25 mg/kg, Sigma-Aldrich) was
suspended in saline containing 5% Tween 80 and maintained at
60uC in the dark, and administered i.p. at a volume of 10 ml/kg
40 min before the start of the test session.
Data Analysis
The amount of PPI was calculated as a percentage score for
each acoustic prepulse trial type: % PPI=1002{[(startle response
for PREPULSE+PULSE)/(startle response for PULSE-
ALONE)]6100}. For statistical analyses, repeated measures
analysis of variance (ANOVA) with genotype as a between subject
factor and drug treatment, block and prepulse intensity as within
subjects factors was performed on the %PPI data. The same
analysis was also performed on the acoustic startle data (PULSE
alone trials). Where appropriate, post hoc analyses were carried
out using Newman-Keuls or Tukey’s test. Alpha level was set to
0.05. All statistical analyses were carried out using the BMDP
statistical software (Statistical Solutions Inc., Saugus, MA).
Results
European Caucasian Families for Bipolar Disorder
Ten SNPs spanning the human SP4 locus were selected from
both public (Genome Browser, UCSC) and proprietary (Celera)
SNP databases (Figure 1). Following genotyping, HAP [25] was
used for an evaluation of the block structure of SP4, and
Haploview [24] was used for an assessment of linkage disequilib-
rium (LD) and association. None of the ten SNPs were found to
deviate from HWE (p.0.05) in this sample, and all were quite
common with minor allele frequencies (MAFs) .0.20.
Table 1 describes the results of the single-SNP association
analyses using the parenTDT test. SNP 7 (rs12673091) showed the
most significant association in the allelewise analyses with a p value
of 0.0005 (permutation p=0.0007) and an overtransmission of the
major (‘‘A’’) allele. This SNP also revealed a genotypic effect with
an overall p value of 0.009. The p values for the A/A and A/G
genotypes were 0.004 and 0.031, respectively, consistent with the
significant overtransmission of the ‘‘A’’ allele in the allelewise
analyses. Three other SNPs (SNP 6, 9, and 10) were nominally
significant, possibly due to their correlations with SNP 7.
Interestingly, one of these SNPs, SNP 9 (rs3735440), is located
within a potential microRNA (miR-145) binding site in the 39
untranslated region of human SP4 gene, and displayed nominally
significant (p=0.019) overtransmission of the ‘‘C’’ allele.
An assessment of LD across the SP4 gene revealed three LD
blocks with a high degree of LD observed between SNPs 6–10, all
of which derive from block 3 and four of which displayed at least
marginal evidence for association (Figure 2a). We therefore
performed haplotypic association analyses on all haplotypes from
block 3 with frequencies .0.01. The results of these analyses are
shown in Table 2. The global p value was 0.004 with one
haplotype (AGTTA) in particular revealing a significant under-
transmission and a p value of 0.0004 (permutation p=0.001). This
haplotype contains the ‘‘G’’ allele of SNP 7, which was the
previously undertransmitted allele in the single SNP analyses.
Another haplotype (CATCT) containing the previously over-
transmitted ‘‘A’’ allele was marginally significant as well.
Phylogenic analyses of haplotypes composed of all ten SNPs, as
shown in Figure 2b, reveal that this overtransmitted block 3
haplotype derives from two related ancestral haplotypes (haplo-
types BO and BP) that form a haplotype cluster of several related
common haplotypes. On the other hand, the significantly under-
transmitted block 3 haplotype (AGTTA) comprises a rather
distinct ancestral haplotype (haplotype A) that is relatively
common but for which there are only a few relatively rare recent
haplotype derivatives. Common haplotypes derived from the other
ancestral haplotype (haplotype BN) did not show an association
with bipolar disorder.
SP4 Gene in Bipolar Disorder
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To provide a replication of these results, the same ten SNPs
were genotyped in a sample of 506 Chinese bipolar cases and 507
controls. SNP10 (rs11974306) was found to deviate from HWE in
this sample and thus removed from further analyses. These SNPs
were generally more rare in the Chinese population with only five
of the ten SNPs displaying MAFs .0.10, suggesting population
differences between individuals of Caucasian and Chinese ancestry
for this gene. Four SNPs differed significantly between cases and
controls. SNP7 (rs12673091) displayed a significant association in
the Chinese bipolar case-control sample with an overtransmission
of the minor (‘‘A’’) allele s (p value, 0.002; permutation p value
0.014), thereby replicating the results of our analyses in the
Caucasian family sample (see Table 1). Moreover, SNP9
(rs3735440) displayed a moderately significant association
(p=0.029) with an overtransmission of the ‘‘C’’ allele in Chinese
population, also replicating our results in the Caucasian family
analyses.
Similar to the Caucasian sample, a high degree of LD between
SNPs 6–9 was observed in the Chinese sample (Figure 2c). Since
three of the four SNPs significantly associated with bipolar
disorder in this sample all lie within this LD block (block 3), we
performed association analyses of all haplotypes composed of these
three SNPs. Two haplotypes CATC (p=0.027) and AGTT
(p=0.04) displayed significant overtransmission and undertrans-
mission, respectively, in this sample, consistent with the observed
associations in the Caucasian families (Table 2).
Chinese Trio Families for Schizophrenia
It has been suggested that both bipolar disorder and
schizophrenia share common genetic risk factors. To explore
whether SP4 gene might also be associated with schizophrenia, we
conducted genetic studies on a sample of 325 Chinese trio families
with schizophrenia. We observed an association between SNP7
(rs12673091) and schizophrenia in the Chinese population
(p=0.012) with a significant overtransmission of the ‘‘A’’ allele
(see Table 1). These results are thus consistent with those for SNP7
in both the Caucasian and Chinese bipolar samples.
All together, we observed a significant genetic association
between human SP4 gene and bipolar disorder and schizophrenia
Figure 1. Human SP4 genomic structure. Ten SNPs were selected from the site 5 kb upstream of human SP4 transcription start site and to the
site 3 kb downstream of its transcription termination. All ten SNPs have good heterozygosity in European Caucasian population according to
HapMap data.
doi:10.1371/journal.pone.0005196.g001
Table 1. Association analysis of SP4 gene with both bipolar disorder and schizophrenia.
SNP # SNP ID Caucasian Families for Bipolar Disorder Chinese Case-Controls for Bipolar Disorder Chinese Trios for Schizophrenia
Alleles* MAF Risk T:U Chisq P Alleles* MAF Risk
Case,
Control Chisq P MAF Risk T:U Chisq P
1 rs10245440 C/A 0.24 A 195:192 0.2 0.647 A/C 0.46 C 0.47, 0.44 1.74 0.187 0.45 C 139:138 0.00 0.955
2 rs10261327 C/T 0.46 C 246:227 0.8 0.379 T/C 0.49 C 0.49, 0.49 0.00 0.953 0.47 C 139:137 0.01 0.908
3 rs40245 T/A 0.38 A 269:251 1.2 0.273 T/A 0.06 A 0.08, 0.05 6.76 0.009
4 rs2282888 A/G 0.39 G 265:231 3.3 0.07 A/G 0.09 G 0.10, 0.08 3.36 0.067
5 rs10276352 A/G 0.44 G 294:268 2.7 0.102 G/A 0.28 G 0.74, 0.71 2.79 0.095 0.28 G 132:122 0.40 0.526
6 rs12668354 A/C 0.33 C 259:216 5.2 0.022 A/C 0.09 C 0.09, 0.08 1.94 0.163
7 rs12673091 A/G 0.28 A 250:186 12 0.0005 G/A 0.13 A 0.15, 0.10 9.47 0.002 0.11 A 76:48 6.32 0.012
8 rs1018954 T/A 0.42 A 279:267 0.3 0.592 T/A 0.04 A 0.05, 0.02 10.22 0.001 0.05 T 39:27 2.31 0.129
9 rs3735440 T/C 0.34 C 274:225 5.5 0.019 T/C 0.08 C 0.10, 0.07 4.79 0.029
10 rs11974306 A/T 0.5 T 298:251 5.6 0.018
*Alleles for each SNP are presented as major/minor, respectively.
Key: MAF=minor allele frequency; Risk=risk allele; T:U=transmitted to untransmitted ratio.
doi:10.1371/journal.pone.0005196.t001
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with the level of human SP4 gene expression, we extracted total
RNA fromthelymphoblastoid cells ofEuropeanCaucasiansamples.
Unfortunately, we could not detect the expression of human SP4
gene by RT-PCR. The neuronal restrictive expression of SP4 gene
prevented our further effort to investigate the effects of the positive
SNPs on the level of human SP4 gene expression. However, the
expression of human SP1 gene, which functionally substitutes with
SP4 gene by recognizing the same DNA binding motif [2] , was
found to be reduced in both prefrontal cortex and striatum of
postmortem brains of schizophrenia patients [30]. Therefore,
reduced expression of SP1 family transcription factors may play an
important role in pathophysiology of schizophrenia and related
disorders. Consistent with this notion, mice with reduced expression
of Sp4 gene displayed deficient sensorimotor gating and memory.
Haploinsufficiency for Mouse Sp4 Gene in Modulating
Sensorimotor Gating
Sensorimotor gating, a putative endophenotype for both
schizophrenia and bipolar disorder, has been studied extensively in
both human patients and animal models [6,31,32,7]. Our previous
studies demonstrated that hypomorphic Sp4 mutant mice, in which
expression of the Sp4 gene is reduced to 2%–5% of the level in
wildtype mice, displayed a variety of behavioral abnormalities
including deficient sensorimotor gating [4]. To further examine
whether the level of Sp4 gene expression has dosage effects on
sensorimotor gating, we conducted prepulse inhibition tests on Sp4
heterozygous mice as well as their sibling wildtype and homozygous
mutant mice. There was a significant Sp4 gene effect on PPI with p
value less than 0.00001 (Figure 3a). Post hoc analysis revealed that
there were significant differences in PPI between wildtype and
heterozygous Sp4 mice at all three different prepulse levels. The
homozygous Sp4 mutants also displayed significantly reduced PPI
relative to heterozygous Sp4 mice which in turn have less PPI than
wildtype siblings, consistent with a gene-dosage effect. No gender
effect was observed in the PPI tests. All mice displayed normal startle
habituation, with no difference among different genotypes in startle
magnitude (Figure 3b). Nevertheless, male mice tend to have higher
magnitude of startle than female mice, presumably due to their
heavier body weight.
Improvement of PPI Deficit with Dopamine D2
Antagonist and Mood Stabilizers
The importance of dopamine neurotransmission for the
pathogenesis of both bipolar disorder and schizophrenia has been
suggested by both the clinical efficacy of dopamine D2 receptor
antagonists in human patients and their central roles in
modulating relevant behaviors in animal models. As in rodent
models of deficient PPI [7,33], the administration of antipsychotics
significantly improved PPI deficits in schizophrenia patients
[34,35]. To examine whether PPI deficits in both Sp4 heterozy-
gous and homozygous mutant mice can be improved by
administration of dopamine D2 receptor antagonists, we conduct-
ed pharmacological reversal of the PPI deficits with the
administration of raclopride. Besides a significant gene effect, a
strong gene X raclopride effect on PPI was observed (gene X drug
interaction p value, 0.0029). No significant effect was observed in
the interactions between gene, raclopride and prepulse intensity.
Therefore, we averaged the prepulse inhibition values across three
different prepulse levels in both vehicle and drug groups. Post hoc
analyses were conducted to compare the average PPI between
vehicle and drug groups in three different genotypes. A significant
improvement of PPI with raclopride was observed in both Sp4
heterozygous and homozygous mice (Figure 4a). Surprisingly, the
administration of raclopride decreased PPI in wildtype mice,
indicating possible drug effects on D2 autoreceptors in the
regulation of dopamine release [36,37]. The observed PPI
improvement in both Sp4 heterozygous and homozygous mice
could therefore be underestimated because of the PPI reduction
caused by D2 autoreceptor inhibition.
Figure 2. The LD pattern of human SP4 gene. (a) Detailed LD structure of SP4 gene in the UCSD/NIMH sample, along with the designation of
the three haplotype blocks, the haplotypes within, and the relationships of haplotypes between blocks. Measures of the strengths of the LD are
indicated within each block, which are color-coded with red being high LD and white being low LD. An (*) indicates a tagging SNP. Heavy solid lines
indicate a frequency .0.10, whereas solid lines indicate a frequency .0.01. The frequencies of each haplotype are indicated to the right. (b)
Predicted phylogeny of the SP4 gene. Solid lines indicate single mutation events in a lineage, and dashed lines indicate recombination events in a
lineage (there are necessarily two sources for each resulting daughter haplotype). ‘‘Ancestral’’, ‘‘common,’’ and ‘‘recent’’ haplotypes are defined in the
Methods section. A ‘‘?’’ in an ancestral haplotype represents the precursor to a mutation, which allows for the presentation of the information that
the two haplotypes are related, knowing where the mutation occurred but not which haplotype is the parent. (c) Details of the LD and haplotype
structure of the SP4 gene in the Chinese BPAD case-control sample.
doi:10.1371/journal.pone.0005196.g002
Table 2. Haplotype analyses of SP4 association in bipolar samples.
Caucasian Families for Bipolar Disorder Chinese Case-Controls for Bipolar Disorder
Block 3
(SNP 6–10) Freq. T:U Chisq. P Value*
Block 3
(SNP6–9) Freq. Case,Control Freq. Chisq. P Value
CATCT 0.31 249.3:215.9 5.50 0.019 CATC 0.082 0.096, 0.069 4.87 0.027
AGTTA 0.25 179.9:229.3 12.45 0.0004 AGTT 0.861 0.846, 0.877 4.22 0.040
AAATA 0.22 195.9:197.8 0.17 0.684 AAAT 0.037 0.046, 0.028 4.69 0.030
AAATT 0.16 140.2:126.2 0.43 0.511
AGATA 0.02 12.8:19.1 1.43 0.232
AGTTT 0.01 15.4:16.5 0.01 0.907
AAACT 0.01 19.0:18.0 0.30 0.585
*Global p=0.004.
doi:10.1371/journal.pone.0005196.t002
SP4 Gene in Bipolar Disorder
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disorder. To study whether mood stabilizers can improve the PPI
deficits, lithium chloride was administered acutely to reverse the
PPI deficits in both Sp4 heterozygous and homozygous mice.
Neither lithium nor gene X lithium effect on PPI was observed
(Figure S1). In contrast, we observed that acute treatment with the
mood stabilizer valproate improved PPI across all three different
genotypes. However, the gene X valproate effect was not
statistically significant due to the PPI increase in wildtype mice
(Figure S1). Carbamazepine, an anticonvulsant used as a mood
stabilizer, also increased PPI across all three genotypes at a dosage
of 50 mg/kg. To minimize nonspecific drug effects, we decreased
the dosage to 25 mg/kg. Surprisingly, we observed significant
improvement of PPI only in female heterozygous mice (Figure 4b).
Both wildtype and homozygous female mice did not respond to
the administration of carbamazepine at this dosage. To confirm
the observation, we examined the effects of carbamazepine on PPI
in a separate Sp4 mouse cohort. We again observed that the
reduced dosage of carbamazepine improved PPI only in female
heterozygous Sp4 mice (data not shown). The differential response
Figure 3. Haploinsufficiency of mouse Sp4 gene in the modulation of prepulse inhibition. The number of mice for the PPI studies were
included in the parentheses after individual genotype (a) Prepulse inhibition at three different prepulse levels. (b) Startle habituation within the PPI
session. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0005196.g003
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indicate the role of Sp4 function in the mediation of carbamaz-
epine drug effect. The failure of PPI improvement in male
heterozygous mice was unexpected, however, the gender effect
was also observed in their differential startle response to
carbamazepine (data not shown) [38].
Discussion
Our previous studies demonstrated a central role for the Sp4
gene in hippocampal development and modulation of a variety of
behaviors relevant to human psychiatric disorders [4,5]. The
findings prompted us to examine whether human SP4 gene may
Figure 4. Improvement of sensorimotor gating with dopamine D2 antagonist raclopride and carbamazepine in Sp4 mutant mice. (a)
A within subject design was used for the raclopride studies. The average PPI values across three different prepulse intensities were used for
comparison. A significant PPI improvement was observed in both Sp4 heterozygous and homozygous mice after the administration of raclopride at
the dosage of 3 mg/kg. The numbers of mice for the PPI studies were included in the parentheses after individual genotype (b) A between subject
design was used for the carbamazepine studies. There were 7 mice in each group of WT-Veh and WT-CBZ mice, 14 mice in each group of Het-Veh and
Het-CBZ mice, 7 mice in each group of Homo-Veh and Homo-CBZ mice. A significant PPI improvement was observed in female Sp4 heterozygous
mice after the administration of carbamazepine at the dosage of 25 mg/kg. * p,0.05.
doi:10.1371/journal.pone.0005196.g004
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association studies, we observed a significant association between
the human SP4 gene and bipolar disorder and schizophrenia in all
three independent samples. It is especially striking that we saw
association of the same alleles and haplotypes in both Caucasian
and Chinese populations. Excessive dopamine transmission has
been proposed in the pathophysiology of both bipolar disorder and
schizophrenia; we therefore examined whether similar disruption
of dopamine neurotransmission occurred in hypomorphic Sp4
mice. As expected, our pharmacological studies suggested that
both dopamine D2 receptor antagonists and mood stabilizers
partially reversed the PPI deficits in Sp4 mutant mice.
Psychiatric disorders are likely caused by multiple susceptibility
genes, each with small effects in increasing the risk of illness [39].
Human population heterogeneity constitutes an enormous chal-
lenge; few susceptibility genes have so far been confirmed
consistently for psychiatric disorders. We conducted two of our
three association analyses in nuclear families, which are more
robust to the effects of population substructure. The associations
were further verified in the Chinese case-control sample, which
complement the design of family studies. Significant overtransmis-
sion of the ‘‘A’’ allele from SNP7 (rs12673091) was observed in
both bipolar and schizophrenia patients in all three independent
samples. The ‘‘A’’ allele of SNP7 (rs12673091) was localized in the
fifth intron of human SP4 gene and is conserved in both
chimpanzee and rabbit, but not in mouse and rat (Figure 5a).
SNP9 (rs3735440) also displayed significant association with
bipolar disorder in both European Caucasian families and Chinese
case-control samples. Interestingly, the overtransmitted ‘‘C’’ allele
was localized in the putative binding site of microRNA (miR-145),
which recognizes a seed sequence eight nucleotides downstream of
the SNP9, in the 39 untranslated region of the human SP4 gene
(Figure 5b). However, both ‘‘T/C’’ alleles cannot base-pair with
the corresponding sequence of miR-145. It has been shown that
unpaired sequence in the microRNA binding site could also play
an important role in the regulation of interactions between
microRNA and its target mRNA [40,41]. In fact, the ‘‘T’’ allele of
the SNP9 was conserved from mouse to human (Figure 5b).
Therefore, the ‘‘C’’ allele of the SNP9 merits further studies as a
potential functional mutation.
In addition to the consistency of single SNP associations in two
different ethnic populations, we also observed that similar
haplotypes significantly associated with bipolar disorder. In the
Caucasian families, the haplotype (AGTTA) from SNP 6–10
(rs12668354, rs12673091, rs1018954, rs3735440, and rs11974306)
was undertransmitted with a p value of 0.0004. Interestingly, a
version of this haplotype (AGTT) from SNP 6–9 (rs12668354,
rs12673091, rs1018954, rs3735440) was also undertransmitted
with p value of 0.0399 in Chinese bipolar patients. Similarly,
haplotypes CATCT and CATC were significantly overtransmitted
in the Caucasian and Chinese populations, respectively. Taken
together, these data provide strong support for the hypothesis that
the SP4 gene functions as a susceptibility gene for bipolar disorder
and possibly for schizophrenia as well, since the two disorders have
overlapping genetic components [42,43]. Unfortunately, the
neuronal restrictive expression of SP4 gene prevented our further
effort to study the association between these positive SNPs/
haplotypes and the level of human SP4 gene expression. However,
decreased expression of human SP1 gene, functionally redundant
with its family member SP4 gene, was reported in the prefrontal
Figure 5. Conservation of sequence polymorphism. Sequence conservation of the SNP 7 (a) and 9 (b) between different species.
doi:10.1371/journal.pone.0005196.g005
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patients [30]. The reduced expression of SP1 family transcription
factors may result in aberrant expression of many downstream
target genes which contribute to the pathophysiology of schizo-
phrenia and related disorders. Consistent with the reduced
expression of SP1 gene in schizophrenia, reduced expression of
mouse Sp4 gene resulted in both hippocampal abnormalities and
deficient sensorimotor gating, two putative endophenotypes for
schizophrenia and related psychiatric disorders. In this study, we
found that the mouse Sp4 gene exhibits haploinsufficiency in the
modulation of sensorimotor gating. This finding may be
particularly relevant to consideration of SP4 as a candidate
susceptibility gene for psychiatric disorders, as considerable
evidence suggests that hypomorphic alleles, instead of loss of
function, of multiple genes contribute to the pathogenesis of
psychiatric disorders [44].
Excessive dopamine neurotransmission has been demonstrated
in both bipolar disorder and schizophrenia. Most clinically
effective antipsychotics are dopamine D2 receptor antagonists.
The administration of raclopride, a dopamine D2 antagonist,
significantly improved sensorimotor gating in both Sp4 hetero-
zygous and homozygous mice but not in wildtype mice,
suggesting that dopamine neurotransmission may be altered in
Sp4 mutant mice as it is in human psychiatric disorders.
Considering significant genetic association between SP4 gene
and bipolar disorder, we also examined the effects of different
mood stabilizers on the reversal of PPI deficits in mutant mice.
The mood stabilizer valproate improved PPI in both wildtype
and Sp4 mutant mice. Acutely administrated carbamazepine
also significantly reversed the PPI deficit in female heterozygous
Sp4 mice. Although we did not observe effects of acutely
administered lithium on PPI improvement, chronic administra-
tion of lithium may be necessary for the reversal of PPI deficits.
Taken together, the pharmacological studies on Sp4 hypomor-
phic mice provided additional support for SP4 gene as a
susceptibility gene for bipolar disorder and schizophrenia. In the
future, it will be interesting to study whether similar pharma-
cogenetic interactions in hypomorphic Sp4 mice may be
conserved in human. Such studies would be valuable for not
only the cross-species validation of the Sp4 mouse model but also
the development of gene-specific diagnosis and treatment.
Our human genetic association studies provide direct evidence
for the human SP4 gene as a susceptibility gene for both bipolar
disorder and schizophrenia. However, the functional mutations in
human SP4 remain to be studied. On the other hand, the
elucidation of Sp4 molecular pathways in the Sp4 hypomorphic
mouse model will provide novel insights in our understanding of
neural circuitry in the regulation of sensorimotor gating and other
behaviors relevant to human psychiatric disorders.
Supporting Information
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Found at: doi:10.1371/journal.pone.0005196.s001 (9.62 MB TIF)
Acknowledgments
The authors thank Sorana Caldwell for technical assistance and Dr.
Victoria Risbrough for statistical analysis.
Data and biomaterials for a portion of the UCSD/UBC/UC families
were collected by A. D. Sadovnick, Department of Medical Genetics,
University of British Columbia, Vancouver, BC, Canada; R. A. Remick,
Department of Psychiatry, St. Paul’s Hospital, Vancouver, BC, Canada;
and Paul E. Keck and Susan L. McElroy, Department of Psychiatry,
University of Cincinnati, Cincinnati, Ohio.
Data and biomaterials were also collected in four projects that
participated in the National Institute of Mental Health (NIMH) Bipolar
Disorder Genetics Initiative. From 1991–98, the Principal Investigators
and Co-Investigators were: Indiana University, Indianapolis, IN, U01
MH46282, John Nurnberger, M.D., Ph.D., Marvin Miller, M.D., and
Elizabeth Bowman, M.D.; Washington University, St. Louis, MO, U01
MH46280, Theodore Reich, M.D., Allison Goate, Ph.D., and John Rice,
Ph.D.; Johns Hopkins University, Baltimore, MD U01 MH46274, J.
Raymond DePaulo, Jr., M.D., Sylvia Simpson, M.D., MPH, and Colin
Stine, Ph.D.; NIMH Intramural Research Program, Clinical Neurogenet-
ics Branch, Bethesda, MD, Elliot Gershon, M.D., Diane Kazuba, B.A.,
and Elizabeth Maxwell, M.S.W.
Data and biomaterials were also collected as part of ten projects that
participated in the National Institute of Mental Health (NIMH) Bipolar
Disorder Genetics Initiative. From 1999–03, the Principal Investigators
and Co-Investigators were: Indiana University, Indianapolis, IN, R01
MH59545, John Nurnberger, M.D., Ph.D., Marvin J. Miller, M.D.,
Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P. Ryan Moe, M.D.,
Nalini Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville),
Husseini Manji, M.D. (at Wayne State University), Debra A. Glitz, M.D.
(at Wayne State University), Eric T. Meyer, M.S., Carrie Smiley, R.N.,
Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M. Dick, Ph.D.,
Howard Edenberg, Ph.D.; Washington University, St. Louis, MO, R01
MH059534, John Rice, Ph.D, Theodore Reich, M.D., Allison Goate,
Ph.D., Laura Bierut, M.D.; Johns Hopkins University, Baltimore, MD,
R01 MH59533, Melvin McInnis M.D., J. Raymond DePaulo, Jr., M.D.,
Dean F. MacKinnon, M.D., Francis M. Mondimore, M.D., James B.
Potash, M.D., Peter P. Zandi, Ph.D, Dimitrios Avramopoulos, and Jennifer
Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini
M.D., Ph.D.; University of California at Irvine, CA, R01 MH60068,
William Byerley M.D., and Mark Vawter M.D.; University of Iowa, IA,
R01 MH059548, William Coryell M.D., and Raymond Crowe M.D.,
University of Chicago, IL, R01 MH59535, Elliot Gershon, M.D., Judith
Badner, Ph.D., Francis McMahon, M.D., Chunyu Liu Ph.D., Alan
Sanders M.D., Maria Caserta, Steven Dinwiddie M.D., Tu Nguyen,
Donna Harakal; University of California at San Diego, CA, R01
MH59567, John Kelsoe, M.D., Rebecca McKinney, B.A.; Rush
University, IL, R01 MH059556, William Scheftner M.D., Howard M.
Kravitz, D.O., M.P.H., Diana Marta, B.S., Annette Vaughn-Brown,
MSN, RN, and Laurie Bederow, MA; NIMH Intramural Research
Program, Bethesda, MD, 1Z01MH002810-01, Francis J. McMahon,
M.D., Layla Kassem, Ph.D, Sevilla Detera-Wadleigh, Ph.D, Lisa Austin,
Ph.D, Dennis L. Murphy, M.D.
Author Contributions
Conceived and designed the experiments: XZ MAG JK. Performed the
experiments: XZ WT SG. Analyzed the data: XZ WT TAG LH MAG JK.
Contributed reagents/materials/analysis tools: TAG. Wrote the paper: XZ
TAG LH MAG JK.
References
1. Heisler LE, Torti D, Boutros PC, Watson J, Chan C, et al. (2005) CpG Island
microarray probe sequences derived from a physical library are representative of
CpG Islands annotated on the human genome. Nucleic Acids Res 33:
2952–2961.
2. Suske G (1999) The Sp-family of transcription factors. Gene 238: 291–
300.
3. Supp DM, Witte DP, Branford WW, Smith EP, Potter SS (1996) Sp4, a member
of the Sp1-family of zinc finger transcription factors, is required for normal
murine growth, viability, and male fertility. Dev Biol 176: 284–299.
4. Zhou X, Long JM, Geyer MA, Masliah E, Kelsoe JR, et al. (2005) Reduced
expression of the Sp4 gene in mice causes deficits in sensorimotor gating and
memory associated with hippocampal vacuolization. Mol Psychiatry 10: 393–406.
5. Zhou X, Qyang Y, Kelsoe JR, Masliah E, Geyer MA (2007) Impaired postnatal
development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes
Brain Behav 6: 269–276.
6. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse
inhibition of startle: normal subjects, patient groups, and pharmacological
studies. Psychopharmacology (Berl) 156: 234–258.
SP4 Gene in Bipolar Disorder
PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e51967. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacolog-
ical studies of prepulse inhibition models of sensorimotor gating deficits in
schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117–154.
8. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, et al. (2003)
Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi
Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum
Genet 73: 601–611.
9. Lerer B, Segman RH, Hamdan A, Kanyas K, Karni O, et al. (2003) Genome
scan of Arab Israeli families maps a schizophrenia susceptibility gene to
chromosome 6q23 and supports a locus at chromosome 10q24. Mol Psychiatry
8: 488–498.
10. Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, et al. (2009) Gene-
wide analyses of genome-wide association data sets: evidence for multiple
common risk alleles for schizophrenia and bipolar disorder and for overlap in
genetic risk. Mol Psychiatry 14: 252–260.
11. Crowe RR, Goedken R, Samuelson S, Wilson R, Nelson J, et al. (2001)
Genomewide survey of panic disorder. Am J Med Genet 105: 105–109.
12. Knowles JA, Fyer AJ, Vieland VJ, Weissman MM, Hodge SE, et al. (1998)
Results of a genome-wide genetic screen for panic disorder. Am J Med Genet 81:
139–147.
13. Bakker SC, van der Meulen EM, Buitelaar JK, Sandkuijl LA, Pauls DL, et al.
(2003) A whole-genome scan in 164 Dutch sib pairs with attention-deficit/
hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and
15q. Am J Hum Genet 72: 1251–1260.
14. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, et al. (1999) A genomic
screen of autism: evidence for a multilocus etiology. Am J Hum Genet 65:
493–507.
15. Wolpert CM, Donnelly SL, Cuccaro ML, Hedges DJ, Poole CP, et al. (2001) De
novo partial duplication of chromosome 7p in a male with autistic disorder.
Am J Med Genet 105: 222–225.
16. Ingram JL, Stodgell CJ, Hyman SL, Figlewicz DA, Weitkamp LR, et al. (2000)
Discovery of allelic variants of HOXA1 and HOXB1: genetic susceptibility to
autism spectrum disorders. Teratology 62: 393–405.
17. Folstein SE, Rosen-Sheidley B (2001) Genetics of autism: complex aetiology for a
heterogeneous disorder. Nat Rev Genet 2: 943–955.
18. Detera-Wadleigh SD, Badner JA, Yoshikawa T, Sanders AR, Goldin LR, et al.
(1997) Initial genome scan of the NIMH genetics initiative bipolar pedigrees:
chromosomes 4, 7, 9, 18, 19, 20, and 21q. Am J Med Genet 74: 254–262.
19. Curtis D, Kalsi G, Brynjolfsson J, McInnis M, O’Neill J, et al. (2003) Genome
scan of pedigrees multiply affected with bipolar disorder provides further support
for the presence of a susceptibility locus on chromosome 12q23–q24, and
suggests the presence of additional loci on 1p and 1q. Psychiatr Genet 13: 77–84.
20. Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, et al. (2008)
Convergent functional genomics of genome-wide association data for bipolar
disorder: Comprehensive identification of candidate genes, pathways and
mechanisms. Am J Med Genet B Neuropsychiatr Genet 150B: 155–181.
21. Nurnberger JI Jr, DePaulo JR, Gershon ES, et al. (1997) Genomic survey of
bipolar illness in the NIMH genetics initiative pedigrees: a preliminary report.
Am J Med Genet 74: 227–237.
22. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, et
al. (1994) Diagnostic interview for genetic studies. Rationale, unique features,
and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849–859;
discussion 863–844.
23. Kelsoe JR, Spence MA, Loetscher E, Foguet M, Sadovnick AD, et al. (2001) A
genome survey indicates a possible susceptibility locus for bipolar disorder on
chromosome 22. Proc Natl Acad Sci U S A 98: 585–590.
24. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
25. Halperin E, Eskin E (2004) Haplotype reconstruction from genotype data using
Imperfect Phylogeny. Bioinformatics 20: 1842–1849.
26. Purcell S, Sham P, Daly MJ (2005) Parental phenotypes in family-based
association analysis. Am J Hum Genet 76: 249–259.
27. Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes.
Genet Epidemiol 25: 115–121.
28. Wang N, Akey JM, Zhang K, Chakraborty R, Jin L (2002) Distribution of
recombination crossovers and the origin of haplotype blocks: the interplay of
population history, recombination, and mutation. Am J Hum Genet 71:
1227–1234.
29. Dudbridge F (2008) Likelihood-based association analysis for nuclear families
and unrelated subjects with missing genotype data. Hum Hered 66: 87–98.
30. Ben-Shachar D, Karry R (2007) Sp1 expression is disrupted in schizophrenia; a
possible mechanism for the abnormal expression of mitochondrial complex I
genes, NDUFV1 and NDUFV2. PLoS ONE 2: e817.
31. Perry W, Minassian A, Feifel D, Braff DL (2001) Sensorimotor gating deficits in
bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50:
418–424.
32. Giakoumaki SG, Roussos P, Rogdaki M, Karli C, Bitsios P, et al. (2007)
Evidence of Disrupted Prepulse Inhibition in Unaffected Siblings of Bipolar
Disorder Patients. Biol Psychiatry.
33. Geyer MA, McIlwain KL, Paylor R (2002) Mouse genetic models for prepulse
inhibition: an early review. Mol Psychiatry 7: 1039–1053.
34. Meincke U, Morth D, Voss T, Thelen B, Geyer MA, et al. (2004) Prepulse
inhibition of the acoustically evoked startle reflex in patients with an acute
schizophrenic psychosis–a longitudinal study. Eur Arch Psychiatry Clin Neurosci
254: 415–421.
35. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, et al. (2006)
Startle gating deficits in a large cohort of patients with schizophrenia:
relationship to medications, symptoms, neurocognition, and level of function.
Arch Gen Psychiatry 63: 1325–1335.
36. Stamford JA, Kruk ZL, Millar J (1988) Actions of dopamine antagonists on
stimulated striatal and limbic dopamine release: an in vivo voltammetric study.
Br J Pharmacol 94: 924–932.
37. Kita JM, Parker LE, Phillips PE, Garris PA, Wightman RM (2007) Paradoxical
modulation of short-term facilitation of dopamine release by dopamine
autoreceptors. J Neurochem 102: 1115–1124.
38. Messiha FS, Butler D, Adams MK (1986) Carbamazepine and ethanol elicited
responses in rodents. Alcohol 3: 131–133.
39. Cannon TD, Keller MC (2006) Endophenotypes in the genetic analyses of
mental disorders. Annu Rev Clin Psychol 2: 267–290.
40. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site
accessibility in microRNA target recognition. Nat Genet 39: 1278–1284.
41. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, et al. (2007)
MicroRNA targeting specificity in mammals: determinants beyond seed pairing.
Mol Cell 27: 91–105.
42. Berrettini W (2003) Bipolar disorder and schizophrenia: not so distant relatives?
World Psychiatry 2: 68–72.
43. Maier W, Zobel A, Wagner M (2006) Schizophrenia and bipolar disorder:
differences and overlaps. Curr Opin Psychiatry 19: 165–170.
44. Gogos JA, Karayiorgou M (2001) ‘‘Targeting’’ schizophrenia in mice. Am J Med
Genet 105: 50–52.
SP4 Gene in Bipolar Disorder
PLoS ONE | www.plosone.org 11 April 2009 | Volume 4 | Issue 4 | e5196